KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBITDA Margin (2016 - 2026)

Boston Scientific's EBITDA Margin history spans 18 years, with the latest figure at 21.16% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 141.0% to 21.16% in Q1 2026 year-over-year; TTM through Mar 2026 was 18.4%, a 217.0% increase, with the full-year FY2025 number at 18.0%, up 246.0% from a year prior.
  • EBITDA Margin hit 21.16% in Q1 2026 for Boston Scientific, up from 15.61% in the prior quarter.
  • Over the last five years, EBITDA Margin for BSX hit a ceiling of 21.16% in Q1 2026 and a floor of 11.29% in Q3 2022.
  • Historically, EBITDA Margin has averaged 16.1% across 5 years, with a median of 15.68% in 2023.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 836bps in 2023 and later crashed -223bps in 2024.
  • Tracing BSX's EBITDA Margin over 5 years: stood at 12.4% in 2022, then increased by 26bps to 15.68% in 2023, then decreased by -6bps to 14.8% in 2024, then rose by 5bps to 15.61% in 2025, then soared by 36bps to 21.16% in 2026.
  • Business Quant data shows EBITDA Margin for BSX at 21.16% in Q1 2026, 15.61% in Q4 2025, and 20.69% in Q3 2025.